Single-Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter Study

Sundar, S.; Jha, T.K.; Thakur, C.P.; Mishra, M.; Singh, V.P.; Buffels, R.
September 2003
Clinical Infectious Diseases;9/15/2003, Vol. 37 Issue 6, p800
Academic Journal
Presents a multicenter study of single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India. Safety profile of the drug; Percentage of cure of the drug; Impact of widespread antimony resistance on the use of amphotericin B; Adverse events seen.


Related Articles

  • Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic... Berman, J.D.; Badaro, R.; Thakur, C.P.; Wasunna, K.M.; Behbehani, K.; Davidson, R.; Kuzoe, F.; Pang, L.; Weerasuriya, K.; Bryceson, A.D.M. // Bulletin of the World Health Organization;1998, Vol. 76 Issue 1, p25 

    Studies the efficacy and safety of liposomal amphotericin B (AmBisome) for treating visceral leishmaniasis (kala-azar) in Brazil, Kenya and India where the disease is endemic. Details on the treatment of 10 patients with AmBisome; Methodology used to conduct the study; Findings of the study.

  • Visceral Leishmaniasis during Childhood in Southern Greece. Maltezou, H.C.; Siafas, C.; Mavrikou, M.; Spyridis, P.; Stavrinadis, C.; Karpathios, Th.; Kafetzis, D. A. // Clinical Infectious Diseases;11/1/2000, Vol. 31 Issue 5, p1139 

    Presents a study of immunocompetent children from southern Greece who were diagnosed with visceral leishmaniasis. Information on visceral leishmaniasis; Evaluation of access to medical services by the patient; Obstacle to the use of liposomal amphotericin B.

  • Immune haemolytic anaemia due to visceral leishmaniasis in a young child: Reply. Dotis, John; Roilides, Emmanuel // European Journal of Pediatrics;2003, Vol. 162 Issue 6, p445 

    Presents the views of the authors on the incidence of immune haemolytic anemia due to visceral leishmaniasis. Need of an urgent and low-cost approach to the treatment of leishmaniasis; Use of the immunochromatographic dipstick test for the diagnosis of leishmaniasis; Difficulties in the use of...

  • Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India.  // PLoS Neglected Tropical Diseases;Apr2014, Vol. 8 Issue 4, p1 

    A correction to the article "Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India" that was published in the 2014 issue is presented.

  • Antileishmanial activity of nano-amphotericin B deoxycholate. Krishna Das Manandhar; Thakur Prasad Yadav; Vijay Kumar Prajapati; Subodh Kumar; Madhukar Rai; Anuradha Dube; Onkar Nath Srivastava; Shyam Sundar // Journal of Antimicrobial Chemotherapy (JAC);Aug2008, Vol. 62 Issue 2, p376 

    Objectives The aim of the present study was to compare the efficacy of a nano form of amphotericin B deoxycholate with that of conventional amphotericin B deoxycholate for the treatment of visceral leishmaniasis. Methods We have formulated nanoparticles (10–20 nM) from amphotericin...

  • Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Chappuis, François; Sundar, Shyam; Hailu, Asrat; Ghalib, Hashim; Rijal, Suman; Peeling, Rosanna W.; Alvar, Jorge; Boelaert, Marleen // Nature Reviews Microbiology;Nov2007, Vol. 5 Issue 11, p873 

    Visceral leishmaniasis (VL) is a systemic protozoan disease that is transmitted by phlebotomine sandflies. Poor and neglected populations in East Africa and the Indian sub-continent are particularly affected. Early and accurate diagnosis and treatment remain key components of VL control. In...

  • Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent. Olliaro, Piero L.; Shamsuzzaman, Tushar A. K. M.; Marasini, Baburam; Dhariwal, A. C.; Be-Nazir, Ahmed; Mondal, Dinesh; Banjara, Megha Raj; Das, Pradeep; Sundar, Shyam; Rijal, Suman; Arana, Byron; Alvar, Jorge; Argaw, Daniel; Peeling, Rosanna W.; Kroeger, Axel; Matlashewski, Greg // PLoS Neglected Tropical Diseases;1/26/2017, Vol. 11 Issue 1, p1 

    The article offers information on the Kala-azar Elimination Programme focusing to eliminate visceral leishmaniasis as a public health problem. It mentions improved treatments for visceral leishmaniasis offered through liposomal amphotericin B, paromomycin, and miltefosine. It also mentions that...

  • Visceral leishmaniasis in a patient with Down syndrome. Colomba, Claudia; Saporito, Laura; Giordano, Salvatore; Infurnari, Laura; Ajovalasit, Patrizia; Titone, Lucina // European Journal of Pediatrics;Feb2006, Vol. 165 Issue 2, p140 

    The article focuses on a case of visceral leishmaniasis that occurred in a child with a cardiopathic condition and Down syndrome. After undergoing a surgical intervention for congenital cardiopathy, a 6-month-old child with Down syndrome returned to paediatric cardiosurgery department with...

  • Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Thakur, C. P.; Kumar, Amit; Mitra, Gaurab; Thakur, Shabnam; Sinha, P. K.; Das, P.; Bhattacharya, S. K.; Sinha, Arun // Indian Journal of Medical Research;Jul2008, Vol. 128 Issue 1, p38 

    Background & objectives: Of the two reservoirs of infection of kala-azar Le., patients of kala-azar and post kala-azar dermal leishmaniasis (PKDL), PKDL provides easy access for the sandfly to pick up the parasites. In the last epidemic of 1977 in India, the importance of PKDL as a potential...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics